BCA
CORT icon

Berman Capital Advisors’s Corcept Therapeutics CORT Stock Holding History

Berman Capital Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$1K Buy
74
+27
+57% +$565 ﹤0.01% 1837
2021
Q2 		$1K Buy
47
+22
+88% +$490 ﹤0.01% 1714
2021
Q1 		$0 Hold
25
– – ﹤0.01% 1785
2020
Q4 		$0 Buy
+25
New +$527 ﹤0.01% 1692

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Berman Capital Advisors's CORT Position: Q3 2021 in Review

Berman Capital Advisors increased its Corcept Therapeutics (CORT) stake by 57% in Q3 2021, buying an estimated $565 and bringing the position to 74 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1837.

Berman Capital Advisors first reported a position in CORT in Q4 2020 and has held it in 4 quarters since. 201 funds tracked by Wall St. Rank hold CORT as of Q3 2021.

  • Berman Capital Advisors held 74 shares of Corcept Therapeutics worth $1K as of Q3 2021.
  • Berman Capital Advisors bought 27 Corcept Therapeutics shares in Q3 2021, an estimated $565.
  • Corcept Therapeutics made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1837 holding.
  • Berman Capital Advisors first reported a position in Corcept Therapeutics in Q4 2020 and has held it in 4 quarters since.
  • 201 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.